TNBC can be classified into four transcriptionally-based subtypes: (1) Luminal androgen receptor (LAR) subtype, characterized by androgen receptor signaling (23%); (2) Immunomodulatory (IM) subtype, defined by high expression of immune cell signaling and cytokine-mediated pathways (24%); (3) Basal-like immunosuppressed (BLIS) subtype, featuring upregulation of cell cycle processes, activation of DNA repair mechanisms, and downregulation of immune response genes (39%); and (4) Mesenchymal-like (MES) subtype, enriched in breast cancer stem cell pathways (15%) (53, 54). This evidence concerns the gene AR and breast cancer.